Method for rapidly testing biological activity of human interleukin-11 on basis of luciferase reporter genes, and construction method and application of cell strains

Patent metadata

Field	Value
Publication number	US-2025388979-A1
Application number	US-202519235522-A
Country	US
Kind code	A1
Filing date	Jun 11, 2025
Priority date	Jun 19, 2024
Publication date	Dec 25, 2025
Grant date	—

Abstract

The present disclosure provides a method for rapidly testing biological activity of human interleukin-11 on the basis of luciferase reporter genes, and a construction method and application of cell strains. The method includes the following steps: 1) constructing cell strains based on luciferase reporter genes; and 2) preparing a sample to be tested into a gradient dilution solution, adding same into a culture solution, then, adding the culture solution into a culture medium containing the cell strains, and after co-incubation, testing the biological activity of human interleukin-11 by determining luciferase activity. The present disclosure successfully constructs a new method for testing the biological activity of interleukin-11 (IL-11). Experimental time is shortened from 48-56 h to 24-28 h by the constructed RGA method, and working efficiency is obviously improved, such that the time cost is saved.

First claim

What is claimed is:

1 . A method for rapidly testing biological activity of human interleukin-11 on the basis of luciferase reporter genes, comprising the following steps:
1. constructing cell strains based on luciferase reporter genes; and 2. preparing a sample to be tested into a gradient dilution solution, adding same into a culture solution, then, adding the culture solution into a culture medium containing the cell strains, and after co-incubation, testing the biological activity of human interleukin-11 by determining luciferase activity.

2 . A construction method for cell strains based on luciferase reporter genes, comprising the following steps:
1. constructing pPR (EXP)-STAT3-luc2 plasmids, which comprises the specific steps: 1-1) synthesizing a promoter: obtaining STAT3 gene action element fragments; 1-2) performing connection and transformation: firstly, digesting a pPR(EXP)-luc2 vector with EcoR I and Sal I, then ligating the digested pPR(EXP)-luc2 vector with the STAT3 gene promoter fragment, and performing transformation into Escherichia coli competent cells after completion of ligation; 1-3) performing screening and verification: spreading the transformed Escherichia coli on a plate containing an antibiotic, performing inverted culture for 12-16 h, selecting bacteria for PCR identification, extracting plasmids from positive colonies, performing digestion to identify recombinant plasmids, sequence positive clones, and extract plasmids after sequencing and alignment is successful, thereby obtaining constructed recombinant expression plasmids of pPR(EXP)-STAT3-luc2;

2 . transfecting cells with the plasmids of pPR(EXP)-STAT3-luc2, which comprises the specific steps:
2-1) performing recovery and culture of HEK293T cells: dissolving cryopreserved HEK293T cells in a 37° C. water bath, performing centrifugation for 5 min at 1360 rpm after the cells are dissolved, removing supernatant through suction, adding 1 mL of a complete medium of cells for resuspension, performing transfer into a T25 culture flask containing 5 mL of a complete medium of cells, and performing culture in an incubator; 2-2) performing cell transfection: seeding the HEK293T cells, performing culture for 24 h, then, adding the cells into a transfection system for culture for 48 h at 37° C., discarding a transfection solution, adding a culture solution, performing passaging at a density of 1:4 when the cells grow close to confluence, continuing culture, and performing positive monoclonal screening when cell confluency reaches 30% to obtain transfected cells;

3 . screening stable cell lines, which comprises the specific steps:
3-1) screening puromycin: washing the transfected cells with phosphate buffer saline (PBS), performing digestion with trypsin, inoculating the cells into a culture dish, then, adding a culture medium containing puromycin, replacing the selective medium every 2-3 days, transferring the cells to a culture flask for continuous culture when the cell confluency is more than 90%, adding a culture medium containing puromycin, selecting monoclonal cells for continuous culture when the transfected cells grow to more than 70%, and adding a culture medium containing puromycin, wherein a concentration of the puromycin is reduced by half at this time; and 3-2) performing monoclonal selection and expanded culture: screening positive clones by a limited dilution method to obtain the cell strains.

3 . The construction method for cell strains based on luciferase reporter genes according to claim 2 , wherein in step 1-1), by consulting literature and NCBI, JASPAR is utilized to predict a promoter region, STAT3 related action elements are screened, four segments of sequences most closely related to human interleukin-11 action are selected, and cleavage sites of EcoRI and SalI are added at both ends of the sequences respectively after the sequences are connected in series as action elements.

4 . The construction method for cell strains based on luciferase reporter genes according to claim 2 , wherein in step 1-2), DH5α competent cells are used as the Escherichia coli competent cells.

5 . The construction method for cell strains based on luciferase reporter genes according to claim 2 , wherein in step 1-3), the antibiotic is ampicillin.

6 . The construction method for cell strains based on luciferase reporter genes according to claim 2 , wherein in step 2-1), the complete medium of cells is a Dulbecco's modified eagle medium (DMEM) culture solution containing double antibiotics of 10% fetal bovine serum and 1% streptomycin, and the culture conditions in the incubator are 5% CO 2 and 37° C.

7 . The construction method for cell strains based on luciferase reporter genes according to claim 2 , wherein in step 2-2), the transfection system comprises 2.5 μg of the pPR (EXP)-STAT3-luc2 plasmid, 1.25 μg of a transposon enzyme plasmid, 5 μL of a P3000 reagent, 3.75 μL of a Lipofectamine 3000 reagent and 250 μL of a DMEM.

8 . The construction method for cell strains based on luciferase reporter genes according to claim 2 , wherein in step 3-2), the steps of screening positive clones by the limiting dilution method comprise: preparing cell suspension, performing cell counting, diluting the cells to 5 cells/mL with a puro culture solution, adding the cell suspension into a 96-well plate at 200 μL/well, wherein a puro concentration is 25 μg/mL, then, adding the cell suspension at 100 μL/well, labeling monoclonal clones under a microscope, after cells in 96 wells are fully grown, transferring the cells into new wells for culture, performing repeated screening, and when the cultured cells basically do not die, performing sequencing identification to obtain the cell strains.

9 . Application of the cell strains based on luciferase reporter genes according to claim 1 in testing of biological activity of human interleukin-11.

Assignees

• Univ Jiliang China

Inventors

• Zhang Yafen
• Ye Zihong
• Wang Yiying
• Tang Jintian

Classifications

• C12Q1/6897 Primary

  involving reporter genes operably linked to promoters · CPC title

• C12N15/70

  Vectors or expression systems specially adapted for E. coli · CPC title

• C12N15/85 Primary

  for animal cells · CPC title

• C12N2510/00

  Genetically modified cells · CPC title

• C12N2800/90

  Vectors containing a transposable element · CPC title